Canaccord’s focus remains on the clinical data for Zoptrex, expected Q1:17
Maxim analyst Jason Kolbert offers commentary on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the biotech firm reported its second-quarter results and …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women’s health, today reported …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that it is expanding its promotion of APIFINY®, the only cancer-specific, non-PSA blood test available to assess the …
Maxim analyst Jason Kolbert remains bullish on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) after the oncology drug maker just made waves signing a licensed agreement …
H.C.
Healthcare analysts explain their bullish views on AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and OraSure Technologies, Inc.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) and Orient EuroPharma Co.
In a research report issued Wednesday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), with a …
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced that its licensee, Sinopharm A-Think Pharmaceuticals Co.